Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin for high-risk outpatients with COVID-19
ACTRN12620000982910Phase 3Not yet recruiting
- Sponsor
- Neuroscience Trials Australia
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivermectin in coronavirus disease 2019 (COVID-19), sponsored by Neuroscience Trials Australia. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12620000982910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000982910.